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Abstract
Background: Families with 46,XY Disorders of Sex Development (DSD) have been reported, but they are
considered to be exceptionally rare, with the exception of the familial forms of disorders affecting androgen
synthesis or action. The families of some patients with anorchia may include individuals with 46,XY gonadal
dysgenesis. We therefore analysed a large series of patients with 46,XY DSD or anorchia for the occurrence in their
family of one of these phenotypes and/or ovarian insufficiency and/or infertility and/or cryptorchidism.
Methods: A retrospective study chart review was performed for 114 patients with 46,XY DSD and 26 patients with
46,XY bilateral anorchia examined at a single institution over a 33 year period.
Results: Of the 140 patients, 25 probands with DSD belonged to 21 families and 7 with anorchia belonged to 7
families. Familial forms represent 22% (25/114) of the 46,XY DSD and 27% (7/26) of the anorchia cases. No case had
disorders affecting androgen synthesis or action or 5 α-reductase deficiency. The presenting symptom was genital
ambiguity (n = 12), hypospadias (n = 11) or discordance between 46,XY karyotyping performed in utero to exclude
trisomy and female external genitalia (n = 2) or anorchia (n = 7). Other familial affected individuals presented with
DSD and/or premature menopause (4 families) or male infertility (4 families) and/or cryptorchidism. In four families
mutations were identified in the genes SRY, NR5A1, GATA4 and FOG2/ZFPM2. Surgery discovered dysgerminoma or
gonadoblastoma in two cases with gonadal dysgenesis.
Conclusions: This study reveals a surprisingly high frequency of familial forms of 46,XY DSD and anorchia when
premature menopause or male factor infertility are included. It also demonstrates the variability of the expression of
the phenotype within the families. It highlights the need to the physician to take a full family history including
fertility status. This could be important to identify familial cases, understand modes of transmission of the
phenotype and eventually understand the genetic factors that are involved.
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Background
The term “disorders of sex development” (DSD) has
been defined as “congenital conditions in which the de-
velopment of chromosomal, gonadal, or anatomical sex
is atypical” [1]. DSD constitutes a spectrum of disorders
that affect the genito-urinary tract and the endocrine-
reproductive system. Anorchia, or embryonic testicular
regression (vanishing testis syndrome), is defined as the ab-
sence of testes in a 46,XY individual with a male phenotype
[2]. It affects one in 20,000 male births [3] and occurs in 1/
177 cases of cryptorchidism [4]. Although some patients
with anorchia present with genital ambiguity [5] or micro-
phallus [6], most have a normal phenotype. The differenti-
ation of the male genital tract and external genitalia is
dependent on anti-Müllerian hormone (AMH) and testos-
terone, suggesting that functional testes were present but
disappeared in utero in these cases. The families of some
patients with anorchia may include individuals with 46,XY
gonadal dysgenesis. This has led to the hypothesis that
anorchia is part of the clinical spectrum of 46,XY gonadal
dysgenesis [7]. We and other investigators have observed a
variable expression of the clinical phenotypes between fam-
ily members carrying the same pathogenic mutation
(NR5A1, GATA4 and FOG2/ZFPM2) [8–10]. Families with
46,XY DSD have been reported, but they are considered to
be exceptionally rare, with the exception of the familial
forms of partial or complete androgen insensitivity [11].
We analyzed data obtained from 114 cases of 46,XY
DSD and 26 cases of anorchia for the occurrence in their
family of one of these phenotypes and/or ovarian insuffi-
ciency and/or infertility and/or cryptorchidism. Our data
are based on the clinical experience of one pediatric endo-
crinologist and reveal a surprisingly high frequency of fa-




A retrospective study chart review was performed for
140 patients evaluated by a senior pediatric endocrinolo-
gist (R Brauner) in a university pediatric hospital at a
single institution between 1981 and 2014 (33 years). This
patient population comprised 114 patients with 46,XY
DSD and 26 patients with 46,XY bilateral anorchia. Of
these 114 patients, 10 had disorders affecting androgen
synthesis (2 patients with 3-β hydroxysteroid dehydrogen-
ase deficiency, 1 patient with CYP11A1 deficiency and 3
patients with 5α-reductase deficiency) or action (4 patients
with partial androgen insensitivity). None of these patients
presented with the familial form. This conclusion was
based on self-reported family history and on clinical as-
sessment of the sibs of the proband.
Among the 32 familial cases included in the present
study, 12 were previously reported as anorchia (n = 7)
[12], gonadal dysgenesis (n = 4) [13] and/or as the first
description of the mutation (n = 3) [8–10].
Methods
The Ethical Review Committee (Comité de Protection des
Personnes, Ile de France IV) approved this study (IRB n°
00003835). The following parameters were extracted from
the medical report: consanguinity, family history relevant
to gonadal anomalies, infertility or precocious menopause
(arrest of menstruations before 40 years [14]), length and
weight at birth, comorbidity or malformations, age and
symptoms at first evaluation. Clinical examination included
an evaluation of the dimensions of the genital tubercle and
the position of the meatus (penoscrotal, midshaft or glan-
dular) and palpation of the labio-scrotal and inguinal areas
for the presence and consistency of the gonads. Internal
genitalia were evaluated by pelvic ultrasound examination
(cases 3–8, 11, 17, 18, 20, and 23), together with magnetic
resonance imaging (MRI) in one patient (case 6) because
the uterus was not observed. Seven patients underwent
genitography (cases 1, 3, 7, 8, 11, 17, and 23). Ultrasound
examination was carried out to assess kidney malforma-
tions (cases 4, 8, 9–12, 14, 16, 17, 18, and 32).
Gonadal dysgenesis was defined by the presence of
Müllerian structures at genitography and/or surgery
and/or histological examination. The patients classified as
having hypospadias had a normal penis length (greater
than 30 mm, −2 SD) [15] and bilaterally or unilaterally
palpable inguinal or intrascrotal gonads. Anorchia was de-
fined as the absence of testicular tissue at surgery or by
the presence of a small nodule of residual fibrous tissue in
a 46,XY individual with a male phenotype.
Nine patients were given testosterone heptylate (3 or
4x100 mg/m2 given IM every 15 days) in the neonatal
period before the sex assignment and/or before the
genitoplasty.
The endocrine evaluation was performed before sur-
gery. In the patients with DSD, congenital adrenal hyper-
plasia (normal basal plasma concentrations of 17-OH
progesterone in all cases) or insufficiency (normal basal
plasma concentrations of adrenocorticotropin hormone
and cortisol in cases 3, 8, 10, 11, 13, 14, 17, 20, 22, and 23)
or a defect of testosterone biosynthesis were excluded. Par-
tial androgen insensitivity was excluded by the clinical-
biological data (low plasma testosterone concentrations
during the first months [16] and an increase in genital tu-
bercle after testosterone administration) and by the ab-
sence of mutation in exons 1 and 2–8 of the receptor gene
in cases 1, 2, 4, 11, 16 and 23–25 (exon 1 not evaluated in
case 23). 5α-reductase deficiency was excluded by measur-
ing the testosterone-to-dihydrotestosterone ratio in the
basal state (cases 1, 2, 3, 10, 11, 12, 13, and 25) or after
stimulation with human chorionic gonadotropin (hCG,
cases 6, 7, 17, 20, and 23) and by the absence of mutation
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in the corresponding gene in cases 11, 16 and 25. Leydig
cell function was evaluated by measuring the basal plasma
testosterone concentration and after stimulation with hCG
(3 or 7×1500 IU, n = 9) with samples taken the day after
the last injection. The hCG test was not performed on pa-
tients with a basal plasma testosterone concentration >
2 ng/mL (except in case 4). Plasma testosterone was mea-
sured by using RIA after extraction with Orion reagents
(Cis biointernational, Gif-sur-Yvette, France). The sensitiv-
ity was 0.07 ng/mL. Plasma hormone concentrations were
measured using different immuno-assays during the study
period. Each new assay method for a given hormone was
always cross-correlated with the previous method to en-
sure that the results are comparable throughout the entire
study period. Plasma concentrations were measured for
AMH (except in cases 7, 17, 20, 28 and 32) and inhibin B
(except in cases 4, 7, 8, 17, 20, 23, 28, 29 and 32) [17–19].
Plasma AMH was measured using the AMH/Müller-
ian-inhibiting substance ELISA kit (Immunotech-Beckman,
Marseille, France). Plasma inhibin B was measured by ELISA
using Oxford Bio-Innovation reagents (Diagnostic Systems
Laboratories-France, Cergy-Pontoise, France). Conventional
histologic examination of the gonads was performed after
gonadectomy (cases 6, 17, and 20) or testicular biopsy (case
25 at 24 years of age).
Genetic analyses
For each patient, cytogenetic analysis was performed on
peripheral blood leukocytes. The chromosome complement
was determined by examining 40–50 metaphases from each
patient. The SRY, NR5A1, GATA4, FOG2, INSL3, LGR8
and MAP3K1 genes were sequenced as previously de-
scribed [20–25] in all patients with DSD until the genetic
diagnosis was determined (except in case 24, for which the
brother, case 16, had been sequenced). In the patients with
anorchia, the complete open reading frames of SRY,
NR5A1, INSL3, MAMLD1 and the T222P variant for LGR8
were sequenced as previously described [20–25].
Results
Of the 140 patients, 25 probands with DSD belonged to
21 families and 7 with anorchia belonged to 7 families.
Familial forms represent 22% (25/114) of the 46,XY DSD
and 27% (7/26) of the anorchia cases. The patients with
familial form were classified according to the presenting
symptom of the index case in two groups: 46,XY DSD
with a female phenotype, genital ambiguity or hypospa-
dias (cases 1 to 25) or 46,XY anorchia (cases 26 to 32,
Fig. 1).
46,XY DSD
Eight patients had comorbidities or somatic anomalies,
including two cases with ectodermal dysplasia (cases 6
and 20), one with a congenital cervical mass of 25x20x8
mm containing epitheloid and/or gigantocellular granu-
lomas (case 4), one with bilateral clinodactyly of the 5th fin-
ger (case 17), three with retarded prenatal (case 13) or
postnatal growth (cases 14 and 22) without defined etiology
and one with bilateral vesico-ureteral reflux (case 15).
The gender of rearing was female in 4 patients with fe-
male presentation or Prader I to III due to gonadal dysgen-
esis (cases 5, 6, 17, 20), and male in 21 patients (Table 1).
There was no change in the gender after this assignment.
The first evaluation was made either prenatally (n = 2), be-
fore the age of 6 months (n = 11), between the age of 6
and 12 months (n = 3) or after one year of age (n = 9). The
presenting symptom was genital ambiguity (n = 12), hypo-
spadias (n = 11) or discordance between 46,XY karyotyp-
ing performed in utero to exclude trisomy and female
external genitalia (cases 5 and 6).
Among the patients evaluated during the first 6 months
of life, 6 patients had basal plasma testosterone concentra-
tions greater than 1 ng/mL and 7 patients had low concen-
trations of plasma testosterone (Table 2). Of these, two had
gonadal dysgenesis (case 5 with a mutation in the SRY gene
and case 6) and also had low or undetectable concentra-
tions of inhibin B and AMH. One had a mutation in the
GATA4 gene (case 7) and one in NR5A1 gene (case 8). The
3 other patients with low testosterone concentrations are
brothers (cases 2, 3, 11) and they had normal plasma in-
hibin B and AMH concentrations. Their maternal uncle
(case 25) had a normal pubertal increase in testosterone
and pubertal development but normal then low inhibin B
associated with azoospermia that was confirmed by testicu-
lar biopsy. After stimulation with hCG, the testosterone
concentration was > 2 ng/mL in 2 of the 7 patients evalu-
ated (cases 4 and 20). The basal plasma follicle stimulating
hormone (FSH) concentration was increased (>9 IU/L) in
2 patients (cases 6 and 17 with gonadal dysgenesis) and
normal in the others who were in the prepubertal age
range, except cases 24 and 25, which were pubertal. The
plasma inhibin B concentrations were normal except in the
cases with gonadal dysgenesis (cases 5 and 6) and in case
14, which was not reevaluated. The plasma AMH concen-
trations were also decreased in cases 5 and 6 and 23, in-
creased in cases 1 and 12, and normal in the others.
Müllerian structures were seen in the 4 cases with go-
nadal dysgenesis at ultrasound evaluation (cases 5 and 20),
genitography (case 17) or MRI (case 6). This was confirmed
at surgery in all cases, except in case 5, in which no oper-
ation had been performed. Surgery discovered right dysger-
minoma in case 6 and right gonadoblastoma in case 20.
Anorchia
No patient presented with somatic anomalies (Table 3).
The mother of case 26 began menstruating at 12 years of
age. She was operated on for scalenus syndrome. She had
a previous medical pregnancy interruption at 20 weeks
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because of hygroma and anasarque. The female fetus had
a 46,XX blood karyotype, intrauterine growth retardation,
retrocervical edema, retrognathism, clinodactyly of the 5th
digit, agenesis of the 12th pair of ribs, and ovaries with
germ cells but no primary follicles. The mother of case 27
began menstruating at 9.5 years of age, then had irregular
menstruation with increased basal plasma FSH concentra-
tions and underwent 4 attempts at in vitro fertilizations
before this pregnancy. After the proband was born, she
underwent insemination, which led to an empty follicle.
Her own mother experienced menopause at 50 years of
age and had a hysterectomy for a fibroma. The father had
a normal spermogram.
At the first evaluation, all patients had unpalpable tes-
tes and normal penis length and morphology, except
case 26, which presented with micropenis. The basal
plasma concentrations of inhibin B, AMH and testoster-
one were very low or undetectable in all of the patients
evaluated. The plasma concentrations of FSH were in-
creased, except in cases 26, 30 and 31. Surgery showed
no testicular tissue (cases 26 and 30) or unilateral or bi-
lateral residues in the others.
Modes of inheritance and genetic analyses
Figure 1 shows the pedigrees of the families. In addition to
the genital anomalies, families reported premature meno-
pause (cases 1, 6, 8, and 32) or infertility (cases 4, 5, 20,
and 28). Assuming that DSD and infertility have the same
genetic basis in these families, the mode of transmission of
the phenotype in all families is suggestive of an autosomal
Fig. 1 Pedigrees of 25 probands (1 to 25) with DSD belonging to 21 families and 7 probands (26 to 32) with anorchia belonging to 7 families.
Squares represent male family members, and circles represent female family members. Symbols containing a black dot represent apparently
unaffected carriers of the mutation
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dominant inheritance with a high degree of incomplete
penetrance. Some pedigrees (eg index case 9 and index
case 17) are indicative of a sex-limited expression. Consan-
guinity was present in case 23, in which the parents were
first cousins. Mutations were identified in one patient with
female external genitalia and 3/12 patients with genital
ambiguity (25%) in the genes SRY (case 5), a heterozygous
NR5A1 mutation (case 8) [8], heterozygous GATA4 (case
7) [9] and heterozygous FOG2/ZFPM2 mutation (case 17)
[10]. The inheritance of the SRY mutation is unknown be-
cause the father’s DNA was not available for study. How-
ever, he has two female cousins who were reported to be
infertile. In each of the 3 other cases, the mother transmit-
ted heterozygous mutation. The mother of case 8, who
carries the NR5A1 mutation, underwent premature meno-
pause. The other mothers carrying mutations in GATA4
or FOG2 had apparently normal ovarian function (detailed
in [9, 10]). In case 17, the heterozygous FOG2/ZFPM2
mutation was carried by the unaffected mother and grand-
mother suggesting that mutations in this gene are associ-
ated with a sex-limited phenotype.
All other patients with DSD were sequenced for the
SRY, NR5A1, GATA4, FOG2, INSL3, LGR8 and MAP3K1
genes, and no pathogenic mutations were identified. All
patients with anorchia were sequenced for SRY, NR5A1,
INSL3, MAMLD1 and the T222P variant of LGR8 and
no pathogenic mutations were identified.
Discussion
We report, for the first time, a large monocentric study
of familial forms of 46,XY DSD. This study shows a
high frequency of the familial forms compared to the
sporadic forms seen over 33 years by the same pediatric
Table 1 Clinical characteristics of 25 patients with familial DSD
Case Sex Age at first
evaluation







before after Right Left
1 M 1 d genital ambiguity IV penoscrotal 15×7 30×12 4×25 s i
2 M 1 d genital ambiguity IV glandular 20×10 4×50 s s
3 M 3 d genital ambiguity IV penoscrotal 25×10 4×50 np np
4 M 3 d genital ambiguity IV penoscrotal 20×8 30×10 4×25 i i
5a F 3 d prenatal karyotype 0 normal np np
6 F 4 d prenatal karyotype I normal np np
7a M 7 d genital ambiguity IV penoscrotal 13 22×15 3×30 i i
8a M 21 d genital ambiguity III penoscrotal 15×10 30×15 4×40 s s
9 M 0.1 y hypospadias IV penoscrotal 30×25 s s
10 M 0.1 y hypospadias IV penoscrotal 30×10 s s
11 M 0.1 y genital ambiguity IV penoscrotal 20×10 28×10 4×37.5 s s
12 M 0.3 y hypospadias IV distal 35×15 s s
13 M 0.4 y genital ambiguity IV midshaft 25×10 3×50 s s
14 M 0.6 y hypospadias IV penoscrotal 40×15 s s
15 M 0.8 y hypospadias IV penoscrotal 35×15 3×50 i i
16 M 0.9 y hypospadias IV midshaft 40×20 s s
17a F 1.5 y genital ambiguity III penoscrotal 5×5 np np
18 M 1.8 y hypospadias IV glandular 35×10 i s
19 M 3 y hypospadias V midshaft 45×15 s s
20 F 3.5 y genital ambiguity II glandular 18 i np
21 M 3.9 y hypospadias IV glandular 50×15 i s
22 M 7.6 y hypospadias IV glandular 45×15 s s
23 M 10 y hypospadias V penoscrotal 40×12 i i
24 M 13.6 y genital ambiguity IV penoscrotal 75×35 np np
25 M 15 y genital ambiguity IV midshaft 65×25 i i
DSD disorders of sex development, i inguinal, s scrotal, np not palpable
aGenetic mutations
Cases 2,3,11 are brothers and case 25 is their maternal uncle. Cases 16 and 24 have the same mother (see pedigree)
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endocrinologist (22% of the DSD and 27% of the anorchia)
when premature menopause or infertility are included.
Biological data
The analysis of the biological data enables us 1) to define
causes of DSD responsible for familial forms (androgen in-
sensitivity, defects of testosterone synthesis, 5α-reductase
deficiency); 2) to evaluate the Leydig and tubular func-
tions; and 3) to compare this function in the same family
and also its evolution with time if the individuals are of
different ages. By this approach congenital adrenal
hyperplasia or insufficiency as well as other causes of fa-
milial DSD were excluded. The plasma concentrations of
testosterone (basal and after hCG test), indicating normal
secretion associated with normal plasma luteinizing hor-
mone (LH) concentrations during the first months, make
the diagnoses of androgen insensitivity [16], defects of tes-
tosterone biosynthesis or Leydig cell hypoplasia less likely.
Interestingly, the 7/13 of the cases evaluated during the
first 6 months of life with low basal testosterone concen-
trations included the 4 in the series with mutation and 3
brothers (See below). In addition, mutations in exons 1
Table 2 Hormonal levels and family history of 25 patients with familial DSD






AMH (pmol/L) Parent (family history)
Before hCG After hCG
1 1 d 2.7 0.7b <0.4b 178b 2348b mother (premature menopause (27 years)
in sister of his mother)
2 7 d 0.3 1.5 <0.4 186 794 mother (DSD in brother, sister and nephew)
3 3 d 0.2 <0.4 <0.4 >400 >600 mother (brother of case 2)
4 3 d 4 5.5 0.8b 1.3b ND 614b father (secondary infertility)
5a 3 d 0.1 0.1 0.4 <3 <1 father (infertility in 2 female cousins)
6 4 d <0.07 <0.07 3.3 11 <10b 1b father (premature menopause (38 years) in cousin)
7a 14 d 0.1 0.25 0.2 3.9 ND mother (DSD in one nephew, congenital
heart disease; brother with micropenis
and cryptorchidism)
8a 23 d 0.2 0.9 0.3 1.8 78b mother (premature menopause (28 years)
9 0.1 y 2 3.6 2.2 272 955 mother (hypospadias in each son of her 2 sisters)
10 0.1 y 2.1 3.2 2.4 176 630 father (cryptorchidism)
11 0.1 y 0.1 4.6 0.92 179 865 mother (brother of cases 2 and 3)
12 0.3 y 1.2 0.9 1 590 1674 father (hypospadias)
13 0.4 y 1 2.4 0.7 347 1129 mother (brother DSD, nephew hypospadias)
father (unilateral cryptorchidism and 2 meatus
urinarus in brothers)
14 5 y 0.7 1 14 1136 brother (hypospadias)
15 0.8 y 0.02 <0.4 0.6 175 1042 father (cryptorchidism)
16 0.8 y <0.05 <0.4 <0.4 253 1245 mother (half brother of case 24)
17a 1.5 y <0.05 <0.05 1.7 45 ND mother (DSD in uncle)
18 1.8 y <0.4 <0.4 94 485 father (hypospadias in brother)
19 3 y <0.07 <0.2 0.47 77 1086 father (hypospadias in brother)
20 3.5 y <0.07 3.3 ND father (infertility in one sister and in
paternal grandmother)
21 3.9 y 0.6 97 593 father (unilateral cryptorchidism
as in cousin)
22 7.6 y ND 44 719 brother (hypospadias)
23 10 y 1.1 1.6 <0.2 1.5 ND 37 brother (left cryptorchidism)
24 13.6 y 1.2 0.9 0.5 217 64 mother (half brother of case 16)
25 15 y 10.3 4.6 4.3 157 165 mother (uncle of cases 2, 3, 11)
aGenetic mutations (reference): case 5 SRY p.W98 C; case 7 GATA4 p.Gly221Arg (9); case 8 NR5A1 c.390delG (8); case 17 FOF2/ZFPM 2p.S402R (10)
Consanguinity reported in case 23
Cases 2,3,11 are brothers and case 25 is their maternal uncle. Cases 16 and 24 has the same mother (see pedigree)
bAge at assays similar except case 1 at 1.2 y, case 4 at 9 y, case 6 at 10 y, case 8 at 8.5 y
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and 2–8 of the androgen receptor gene were excluded in
8 patients, including 1/2 with increased plasma AMH
concentrations [19]. These concentrations, as well as those
of inhibin B, provide information on the tubular function
during childhood. They are undetectable in the patients
with anorchia and in those with gonadal dysgenesis. Thus,
in the patient carrying the SRY mutation, there was dis-
cordance between the 46,XY karyotype in utero and the
absence of virilization of the external genitalia. The un-
detectable levels of testosterone and AMH in the amniotic
fluid also excluded androgen insensitivity and suggested
gonadal dysgenesis.
Phenotypic variability
We and other investigators have observed variable ex-
pression of the clinical phenotypes as well as incomplete
penetrance among family members carrying the same
pathogenic mutation. Although rare, phenotypically nor-
mal brothers, fathers and paternal uncles of patients car-
rying the same SRY have been described [11]. None of
these mutations has been found by population screening
of large populations of unaffected 46,XY men. Many
cases of DSD may be are familial rather than sporadic,
as sometimes the effect on the phenotype can be so mild
that the unsuspecting clinician may not diagnose mildly
affected individuals until a more severely affected family
members seeks medical attention. Baetens et al. [26] re-
ported an NR5A1 mutation in a proband with hypospa-
dias and in his asymptomatic mother (regular menses at
30 years of age), maternal aunt (who had been diagnosed
with primary ovarian insufficiency at 35), and maternal
grandfather (who had been operated on for proximal
hypospadias but spontaneously fathered the two girls).
Camats et al. [27] suggested that the phenotypic variabil-
ity may be a manifestation of the time-dependent deteri-
oration of gonadal tissue and/or steroid secretion. In our
study, one family included three brothers (cases 2, 3 and
11) who were evaluated in the neonatal period and had
similar biological presentations, with normal plasma
concentrations of inhibin B and AMH but low basal
plasma testosterone concentrations. Their maternal
uncle (case 25) also presented at 15 years of age with
DSD and had normal adult concentrations of testoster-
one but developed azoospermia, despite initial normal
inhibin B and AMH concentrations, suggesting testicular
regression. Genomic sequencing may help to determine
the source of this variability by revealing genetic modi-
fiers that likely result from interactions between coding
and regulatory variants resulting in an increased pene-
trance of rare pathogenic coding mutations [28].
We included patients with anorchia in this study be-
cause the familial occurrence of anorchia [2, 3, 5] and its
association with other anomalies including gonadal dys-
genesis suggest a genetic origin, but the genetic cause re-
mains unknown, except in one case, which was reported
to carry an NR5A1 mutation [29]. The families of some
patients with anorchia may include other individuals
with pure or partial 46,XY gonadal dysgenesis. This has
led to the hypothesis that anorchia is part of the clinical
spectrum of 46,XY gonadal dysgenesis [7]. However, ex-
ploratory laparoscopy has suggested that at least some
cases of anorchia are the result of prenatal testicular vas-
cular accident associated with torsion during testicle
descent [30].
We report a family history of reproductive problems
in 6/25 (24%) patients with DSD and in 2/7 (29%) pa-
tients with anorchia. Two fathers are secondarily azoo-
spermic and two mothers presented with premature
menopause, suggesting a deterioration of their gonadal
tissue over time. A link between gonadal development
and infertility is becoming more evident as our under-
standing of the genes involved in gonad formation in-
creases. For example, mutations in NR5A1 cause DSD as
well as male [31] and female infertility [8].
Table 3 Characteristics of 7 patients with familial form of anorchia




LH (IU/L) FSH (IU/L) Inhibin B
(pg/mL)
AMH (pmol/L) Parent (family history)
Right Left
26 p np 1d ND <0,4b <0,4b und 5 mother and fetus sister (see Results)





3.2y 0.15 6b 34b ND ND father (secondary infertility with
oligoasthenospermia)
29 ND ND 2y unda <0,2b 18b ND und father (increased basal plasma FSH
concentration (12 IU/L) at 38 y)
30 ND ND 6.2y unda 0.5 0.05 und und mother (cryptorchidism in cousin)
31 ND 8.2y ND 2.8 und und father (cryptorchidism in son of sister)
32 np np 13.6y 0.09 25 122 ND ND mother (premature menopause at 28 y)
ND not determined, und undetectable
aNo increase in testosterone after hCG test
bAge at assays similar except case 26 at 0.8 y, 28 at 12.6, 29 at 6 y
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Genetic analyses
A mutation associated with the phenotype was found in
4/14 patients presenting with ambiguous genitalia. Bar-
seghyan et al. [32] recently found that reported data sug-
gest that 15% of 46,XY gonadal dysgenesis cases are due
to SRY mutations, 13% to mutations in NR5A1, 10–18%
to MAP3K1 variants, and a few cases to other rare gen-
etic causes. The risk of malignancy is estimated to be ap-
proximately 30% in 46,XY individuals with DSD [33].
Among the 3 patients who underwent gonadectomies
because of gonadal dysgenesis, two had gonadoblastoma
and/or dysgerminoma, while the third operated on at
2 years of age had no tumor. This suggests that informa-
tion to make an accurate diagnosis as well as informa-
tion on the wider family members by the physician is of
great importance. We did not perform this step, as it is
sensitive in terms of the relationships and information
sharing within the families.
Study limitations
The present study has limitations because it is retro-
spective. No biological data of the affected members are
available. The link between the DSD or anorchia of the
proband and the symptoms in his/her family is probable
but not confirmed, except in 75% of families carrying
the mutation. Other causes of premature menopause or
infertility were not excluded, as only one mother shares
the NR5A1 mutation with her son. We have no data on
the infertility. Two fathers (of cases 4 and 28) were ex-
plored for secondary infertility, one of them has oli-
goasthernospermia. We retained cryptorchidism as a
possible marker of familial form in 3 fathers (also
present in a cousin in one case) and in one brother of
the only patient of this series with consanguinity. Andro-
gen insensitivity was excluded by the absence of muta-
tion in only 8 patients, but the clinical-biological and
evolutive (increase of the genital tubercle after testoster-
one administration) data make this diagnosis less likely.
The exclusion of the diagnosis of 5α-reductase defi-
ciency was based on the normal testosterone to dihydro-
testosterone ratio, except in 3 cases where a mutation
was excluded. There have been instances reported in the
littérature of affected individuals who did not meet this
hormonal criteria [34].
Conclusions
This study is the first to demonstrate the high frequency
of familial forms of 46,XY DSD and anorchia when pre-
mature menopause and male infertility are included. It
also demonstrates the high variability of the expression
of the phenotype within the families and the probable
deterioration of fertility indicated by secondary sterility
in two fathers and by premature menopause in two
mothers. It poses the question of the risk of malignancy
in the other affected members of the families, particu-
larly in those with gonadal dysgenesis, as the collection
of information within the families on this subject is diffi-
cult. The study also highlights the need to the physician
to gather information on the fertility status of other
members of the family. This could be important to iden-
tify familial cases, understand modes of transmission of
the phenotype and eventually understand the genetic
factors that are involved.
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